Dr Reddy's announces commercial launch of DRDO's anti-COVID-19 drug 2DG
By MYBRANDBOOK
Hyderabad-based Dr Reddy’s Laboratory announced the commercial launch of the anti-Covid-19 drug, 2-Deoxy-D-Glucose (2-DG) for hospitalized moderate to severe Covid-19 patients.
The anti-Covid therapeutic application of 2-DG has been jointly developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), and Dr Reddy’s Laboratories.
The drug will be supplied to both Government and private Covid-19 health facilities across India. “ The drugs initially will be available at hospitals across metros and Tier 1 cities and in later course expand coverage to rest of the nation, said a company statement and the maximum selling price has been capped at ₹990, with a discounted rate offered to government institutions, it said.
The government institutions will receive at a subsidized rate. Satish Reddy, Chairman, Dr. Reddy’s in the official statement said that 2-DG is another addition to the company’s existing COVID-19 treatment portfolio for mild to moderate and severe conditions and includes a vaccine.
Dr Reddy’s has signed an agreement to distribute Russia’s Covid-19 vaccine Sputnik V in partnership with Snowman Logistics. The Defense Minister, Rajnath Singh had earlier announced that he would personally honour the scientists who played a critical role in the development of the drug as they deserve credit for this achievement.
As per the sources, 2-DG, made of the generic molecule along with an analogue of glucose, accumulates in the virus-infected cells of the body and prevents the invasion of the virus from one cell to another. Viral synthesis and energy production of the virus is cut short stopping it to grow faster helping Covid patients to no longer depend on supplemental oxygen and recover faster.
Initial trials for the drug were conducted between May and October last year at 110 patients at six hospitals. The final phase of the clinical trials was concluded in March 2021 on 220 patients at 27 Covid hospitals. The data from the 2-DG trials suggested the drug usage was safe and Covid-19 patients showed significant recovery.
BHIM to join e-commerce, competing with PhonePe and Google Pay
The government-supported payment software BHIM is getting ready to join t...
The latest version of X helps prevent deepfakes on social medi
To combat deepfakes and shallowfakes, Elon Musk revealed a new update t...
India and Namibia collaborate on a payment system similar to U
Once operational, the platform will enable digital transactions in Namibia,...
Sebi issues show-cause notices to six Adani group firms
Sebi issued show-cause notices to six Adani Group firms, including Adani ...
SECUREYE SERVICES PVT. LTD.
TVS ELECTRONICS LTD.
LUMINOUS POWER TECHNOLOGIES PVT. LTD.
TALLY SOLUTIONS PVT. LTD.
Technology Icons Of India 2023: Vijay Shekhar Sharma
Vijay Shekhar Sharma is an Indian technology entrepreneur and billiona...
Technology Icons Of India 2023: Nikhil Rathi
Nikhil Rathi, Co-founder & CEO of Web Werks, a global leader in Data C...
Technology Icons Of India 2023: Lt Gen (Dr.) Rajesh Pant (Retd.)
LT Gen(Dr.) Rajesh Panth (Retd.), National cyber security coordination...
TCIL continues to strengthen India with its technology expertise
TCIL undertakes consultancy & turnkey projects in the field of Telecom...
EESL encouraging e-mobility adoption across India
Energy Efficiency Services Limited (EESL) is a Super Energy Service Co...
INDIANOIL helps reach precious petroleum fuels to every nook and corner of the country
IndianOil, a diversified, integrated energy major with presence in alm...
INGRAM MICRO INDIA PVT. LTD.
Ingram Micro India, a large national distributor offers a comprehensiv...
TECH DATA, A TD SYNNEX COMPANY
Tech Data Corporation was an American multinational distribution compa...
TECHNOBIND SOLUTIONS PVT. LTD.
TechnoBind’s business model is focused on identifying and partnering...